PortfoliosLab logoPortfoliosLab logo
QVCGA vs. KPTI
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

QVCGA vs. KPTI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in QVC Group Inc (QVCGA) and Karyopharm Therapeutics Inc. (KPTI). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


QVCGA

1D
0.00%
1M
YTD
6M
1Y
3Y*
5Y*
10Y*

KPTI

1D
5.56%
1M
7.34%
YTD
29.08%
6M
36.69%
1Y
117.89%
3Y*
-33.36%
5Y*
-42.77%
10Y*
-22.47%
*Multi-year figures are annualized to reflect compound growth (CAGR)

QVCGA vs. KPTI - Yearly Performance Comparison


2026 (YTD)
QVCGA
QVC Group Inc
0.00%
KPTI
Karyopharm Therapeutics Inc.
5.79%

Fundamentals

Market Cap

QVCGA:

$2.75M

KPTI:

$234.79M

EPS

QVCGA:

-$302.09

KPTI:

-$13.00

PS Ratio

QVCGA:

0.00

KPTI:

0.94

Total Revenue (TTM)

QVCGA:

$9.23B

KPTI:

$151.12M

Gross Profit (TTM)

QVCGA:

$2.89B

KPTI:

$145.13M

EBITDA (TTM)

QVCGA:

$789.00M

KPTI:

-$93.05M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

QVCGA vs. KPTI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

QVCGA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.


KPTI
KPTI Risk / Return Rank: 7979
Overall Rank
KPTI Sharpe Ratio Rank: 7979
Sharpe Ratio Rank
KPTI Sortino Ratio Rank: 8080
Sortino Ratio Rank
KPTI Omega Ratio Rank: 7676
Omega Ratio Rank
KPTI Calmar Ratio Rank: 8080
Calmar Ratio Rank
KPTI Martin Ratio Rank: 8080
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

QVCGA vs. KPTI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for QVC Group Inc (QVCGA) and Karyopharm Therapeutics Inc. (KPTI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


QVCGAKPTIDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.25

Calmar ratioReturn relative to maximum drawdown

2.45

Martin ratioReturn relative to average drawdown

6.05

QVCGA vs. KPTI - Sharpe Ratio Comparison


Loading charts...

Drawdowns

QVCGA vs. KPTI - Drawdown Comparison

The maximum QVCGA drawdown since its inception was 0.00%, smaller than the maximum KPTI drawdown of -99.50%. Use the drawdown chart below to compare losses from any high point for QVCGA and KPTI.


Loading charts...

Drawdown Indicators


QVCGAKPTIDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-99.50%

+99.50%

Max Drawdown (1Y)

Largest decline over 1 year

-48.36%

Max Drawdown (3Y)

Largest decline over 3 years

-88.71%

Max Drawdown (5Y)

Largest decline over 5 years

-98.36%

Max Drawdown (10Y)

Largest decline over 10 years

-99.15%

Current Drawdown

Current decline from peak

0.00%

-98.66%

+98.66%

Average Drawdown

Average peak-to-trough decline

0.00%

-75.35%

+75.35%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.57%

Volatility

QVCGA vs. KPTI - Volatility Comparison


Loading charts...

Volatility by Period


QVCGAKPTIDifference

Volatility (1M)

Calculated over the trailing 1-month period

25.79%

Volatility (6M)

Calculated over the trailing 6-month period

62.12%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

94.03%

-94.03%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

94.87%

-94.87%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

86.48%

-86.48%

Dividends

QVCGA vs. KPTI - Dividend Comparison

Neither QVCGA nor KPTI has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

QVCGA vs. KPTI - Financials Comparison

This section allows you to compare key financial metrics between QVC Group Inc and Karyopharm Therapeutics Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B20222023202420252026
2.68B
35.07M
(QVCGA) Total Revenue
(KPTI) Total Revenue
Values in USD except per share items

QVCGA vs. KPTI - Profitability Comparison

The chart below illustrates the profitability comparison between QVC Group Inc and Karyopharm Therapeutics Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20222023202420252026
22.7%
96.2%
Portfolio components
QVCGA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, QVC Group Inc reported a gross profit of 608.00M and revenue of 2.68B. Therefore, the gross margin over that period was 22.7%.

KPTI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a gross profit of 33.72M and revenue of 35.07M. Therefore, the gross margin over that period was 96.2%.

QVCGA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, QVC Group Inc reported an operating income of 106.00M and revenue of 2.68B, resulting in an operating margin of 4.0%.

KPTI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported an operating income of -26.76M and revenue of 35.07M, resulting in an operating margin of -76.3%.

QVCGA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, QVC Group Inc reported a net income of -37.00M and revenue of 2.68B, resulting in a net margin of -1.4%.

KPTI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a net income of -22.39M and revenue of 35.07M, resulting in a net margin of -63.9%.


Portfolio Optimizer

Find the right allocation for QVCGA and KPTI

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer